3Development of the guideline

3.1. What is a NICE clinical guideline?

NICE clinical guidelines are recommendations for the care of individuals in specific clinical conditions or circumstances within the NHS – from prevention and self-care through primary and secondary care to more specialised services. We base our clinical guidelines on the best available research evidence, with the aim of improving the quality of healthcare. We use predetermined and systematic methods to identify and evaluate the evidence relating to specific review questions.

NICE clinical guidelines can:

• provide recommendations for the treatment and care of people by health professionals
• be used to develop standards to assess the clinical practice of individual health professionals
• be used in the education and training of health professionals
• help patients to make informed decisions
• improve communication between patient and health professional

While guidelines assist the practice of healthcare professionals, they do not replace their knowledge and skills.

We produce our guidelines using the following steps:

• Guideline topic is referred to NICE from the Department of Health
• Stakeholders register an interest in the guideline and are consulted throughout the development process.
• The scope is prepared by the National Clinical Guideline Centre (NCGC)
• The NCGC establishes a guideline development group
• A draft guideline is produced after the group assesses the available evidence and makes recommendations
• There is a consultation on the draft guideline.
• The final guideline is produced.

The NCGC and NICE produce a number of versions of this guideline:

• the full guideline contains all the recommendations, plus details of the methods used and the underpinning evidence
• the NICE guideline lists the recommendations
• information for the public (‘understanding NICE guidance’ or UNG) is written using suitable language for people without specialist medical knowledge.

This version is the full version. The other versions can be downloaded from NICE at www.nice.org.uk

3.2. Remit

NICE received the remit for this guideline from the Department of Health. They commissioned the NCGC to produce the guideline.

The remit for this guideline is:

• The Department of Health has asked NICE: ‘to produce a clinical guideline on the management of psoriasis’.

3.3. Who developed this guideline?

A multidisciplinary Guideline Development Group (GDG) comprising professional group members and consumer representatives of the main stakeholders developed this guideline (see section on Guideline Development Group Membership and acknowledgements).

The National Institute for Health and Clinical Excellence funds the National Clinical Guideline Centre (NCGC) and thus supported the development of this guideline. The GDG was convened by the NCGC and chaired by Catherine Smith in accordance with guidance from the National Institute for Health and Clinical Excellence (NICE).

The group met every four weeks during the development of the guideline. At the start of the guideline development process all GDG members declared interests including consultancies, fee-paid work, share-holdings, fellowships and support from the healthcare industry. At all subsequent GDG meetings, members declared arising conflicts of interest, which were also recorded (Appendix B).

Members were either required to withdraw completely or for part of the discussion if their declared interest made it appropriate. The details of declared interests and the actions taken are shown in Appendix B.

Staff from the NCGC provided methodological support and guidance for the development process. The team working on the guideline included a project manager, research fellows, health economists and information scientists. They undertook systematic searches of the literature, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate and drafted the guideline in collaboration with the GDG.

3.4. What this guideline covers

Groups covered in this guideline are children and adults with a diagnosis of psoriasis. Consideration is given to the specific needs, if any, of people with psoriatic arthritis.

Key clinical issues covered:

• Evaluation of disease severity and impact on people with psoriasis.
• Identification of psoriatic arthritis.
• Management of psoriasis including, for example:
  • topical therapy:

    –

    corticosteroids

    –

    vitamin D analogues

    –

    coal tar (with or without phototherapy)

    –

    dithranol (with or without phototherapy)

  • phototherapy (narrow band UVB)
  • photochemotherapy (psoralen and UVA)
  • systemic therapy:

    –

    ciclosporin

    –

    methotrexate

    –

    acitretin.

Note that guideline recommendations will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline will assume that prescribers will use a drug’s summary of product characteristics to inform decisions made with individual patients.

• Self-management.
• Management of the psychological impact of psoriasis.
• Combination and sequencing of treatments.

For further details please refer to the scope in Appendix A and review questions in section 4.1.

3.5. What this guideline does not cover

Groups not covered in this guideline are children and adults who do not have a diagnosis of psoriasis.

Key clinical issues not covered:

• Diagnosis.
• Management of psoriatic arthritis.
• Complementary and alternative treatments.
• Fumaric acid esters^a.

3.6. Relationships between the guideline and other NICE guidance